Zentalis Pharmaceuticals (NASDAQ:ZNTL) Insider Sells $16,683.48 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Vincent Vultaggio sold 6,894 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $2.42, for a total transaction of $16,683.48. Following the completion of the transaction, the insider directly owned 146,506 shares of the company’s stock, valued at $354,544.52. This trade represents a 4.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Vincent Vultaggio also recently made the following trade(s):

• On Monday, February 9th, Vincent Vultaggio sold 3,379 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.39, for a total transaction of $8,075.81.
• On Friday, February 6th, Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93.
• On Tuesday, February 3rd, Vincent Vultaggio sold 556 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.52, for a total transaction of $1,401.12.
• On Monday, February 2nd, Vincent Vultaggio sold 2,540 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.55, for a total transaction of $6,477.00.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL remained flat at $2.40 during trading on Tuesday. 486,299 shares of the stock traded hands, compared to its average volume of 823,857. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $3.95. The firm has a market cap of $173.40 million, a P/E ratio of -1.16 and a beta of 1.73. The stock has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.12. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

ZNTL has been the topic of several research reports. Leerink Partners restated a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Morgan Stanley reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 12th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $5.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC increased its position in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares during the period. Vanguard Group Inc. boosted its position in Zentalis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares during the last quarter. Acadian Asset Management LLC boosted its position in Zentalis Pharmaceuticals by 4.7% during the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after acquiring an additional 124,985 shares during the last quarter. Bank of America Corp DE grew its holdings in Zentalis Pharmaceuticals by 117.1% during the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after acquiring an additional 835,466 shares during the period. Finally, Tybourne Capital Management HK Ltd. raised its position in shares of Zentalis Pharmaceuticals by 53.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after acquiring an additional 516,666 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.